Tumor Biology

, Volume 37, Issue 12, pp 15501–15507 | Cite as

RETRACTED ARTICLE: MiR-200 suppresses metastases of colorectal cancer through ZEB1

  • Jiwei Sun
  • Wenjun Ding
  • Jiajun Zhi
  • Wei Chen
Original Article


Poor prognosis of some colorectal cancer (CRC) cases largely results from early metastases of CRC to the distal organs. Thus, suppression of the invasion of CRC appears to be crucial therapy. Since microRNAs (miRNAs) play critical roles in the regulation of cancer metastases, identification of the involved miRNAs may provide novel therapeutic targets for CRC treatment. Here, we showed that the levels of miR-200 were significantly decreased and the levels of ZEB1 were significantly increased in the CRC specimens from patients, compared to the paired non-tumor tissue. Moreover, the levels of miR-200 and ZEB1 are inversely correlated. Bioinformatics analyses showed that miR-200 targeted the 3′-UTR of ZEB1 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay. Moreover, miR-200 overexpression inhibited ZEB1-mediated cell invasiveness, while miR-200 depletion increased ZEB1-mediated cell invasiveness in CRC cells. Together, our data suggest that miR-200 suppression in CRC cells may promote ZEB1-mediated cancer metastasis. Our work thus highlights a novel molecular regulatory machinery that regulates metastases of CRC.


Colorectal cancer ZEB1 miR-200 


Conflict of interest

The authors have declared that no competing interests exist.


  1. 1.
    East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention–more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.PubMedGoogle Scholar
  4. 4.
    Chai J, Wang S, Han D, Dong W, Xie C, Guo H. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol. 2015;36:1313–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Chu D, Zheng J, Li J, Li Y, Zhang J, Zhao Q, et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol. 2014;35:9787–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/beta-catenin pathway downregulating. Tumour Biol. 2015;36:1701–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, et al. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 2015;36:719–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, et al. Periostin mediates TGF-beta-induced epithelial mesenchymal transition in prostate cancer cells. Cell Physiol Biochem. 2015;36:799–809.CrossRefPubMedGoogle Scholar
  9. 9.
    Sa Y, Li C, Li H, Guo H. TIMP-1 induces alpha-smooth muscle actin in fibroblasts to promote urethral scar formation. Cell Physiol Biochem. 2015;35:2233–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Lan A, Qi Y, Du J. Akt2 mediates TGF-beta1-induced epithelial to mesenchymal transition by deactivating GSK3beta/snail signaling pathway in renal tubular epithelial cells. Cell Physiol Biochem. 2014;34:368–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Teng Y, Zhao L, Zhang Y, Chen W, Li X. Id-1, a protein repressed by miR-29b, facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem. 2014;33:717–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Guo Y, Lang X, Lu Z, Wang J, Li T, Liao Y, et al. MiR-10b directly targets ZEB1 and PIK3CA to curb adenomyotic epithelial cell invasiveness via upregulation of e-cadherin and inhibition of Akt phosphorylation. Cell Physiol Biochem. 2015;35:2169–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Di Leva G, Croce CM. MiRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35:499–515.CrossRefPubMedGoogle Scholar
  20. 20.
    Fang Y, Sun B, Xiang J, Chen Z. MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiol Biochem. 2015;35:227–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gravgaard KH, Lyng MB, Laenkholm AV, Sokilde R, Nielsen BS, Litman T, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207–17.CrossRefPubMedGoogle Scholar
  23. 23.
    Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, et al. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene. 2012;31:3051–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, Goodall GJ. The microRNA-200 family regulates epithelial to mesenchymal transition. Scientific World Journal. 2008;8:901–4.CrossRefPubMedGoogle Scholar
  25. 25.
    von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.CrossRefGoogle Scholar
  26. 26.
    Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Colorectal SurgeryXinhua Hospital Affiliated to Shanghai JiaoTong University School of MedicineShanghaiChina

Personalised recommendations